Provided by Tiger Trade Technology Pte. Ltd.

Biocryst Pharmaceuticals

9.33
-0.2300-2.41%
Post-market: 9.370.0400+0.43%19:55 EDT
Volume:4.32M
Turnover:40.90M
Market Cap:2.34B
PE:7.71
High:9.73
Open:9.59
Low:9.33
Close:9.56
52wk High:11.31
52wk Low:6.00
Shares:250.80M
Float Shares:218.00M
Volume Ratio:0.45
T/O Rate:1.98%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.21
EPS(LYR):1.21
ROE:587.33%
ROA:43.21%
PB:-19.64
PE(LYR):7.71

Loading ...

BioCryst Pharmaceuticals Inc : Needham Cuts Target Price to $18 From $20

THOMSON REUTERS
·
Nov 04, 2025

BioCryst (BCRX) Gets a Buy from Needham

TIPRANKS
·
Nov 04, 2025

Stock Track | BioCryst Pharmaceuticals Plummets 5.33% as Q3 Revenue Misses Estimates Despite EPS Beat

Stock Track
·
Nov 03, 2025

BioCryst Pharmaceuticals Q3 EPS USD 0.06

Reuters
·
Nov 03, 2025

BioCryst reports Q3 adjusted EPS 16c, consensus 8c

TIPRANKS
·
Nov 03, 2025

BioCryst Pharma Q3 Adj. EPS $0.16 Beats $0.04 Estimate, Sales $159.395M Miss $162.974M Estimate

Benzinga
·
Nov 03, 2025

BioCryst Pharmaceuticals reports Q3 ORLADEYO net revenue of $159.1 million and operating profit of $29.6 million

Reuters
·
Nov 03, 2025

BioCryst Pharmaceuticals Inc: Raising Its Outlook for Full Year 2025 Global Net Orladeyo Revenue to Between $590 Mln and $600 Mln

THOMSON REUTERS
·
Nov 03, 2025

BioCryst Pharmaceuticals Inc: Lowering Its Outlook for 2025 Adj Operating Expenses to Between $430 Mln and $440 Mln

THOMSON REUTERS
·
Nov 03, 2025

BioCryst Pharmaceuticals Inc: Company Remains on Track to Deliver Net Income and Positive Cash Flows for Full Year 2025

THOMSON REUTERS
·
Nov 03, 2025

BioCryst Pharmaceuticals Q3 Operating Expenses USD 129.804 Million

THOMSON REUTERS
·
Nov 03, 2025

Stock Track | BioCryst Pharmaceuticals (BCRX) Surges 5.33% Pre-Market Ahead of Q3 Earnings Report

Stock Track
·
Nov 03, 2025

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Nov 03, 2025

Assessing BioCryst Pharmaceuticals (BCRX) Valuation After Recent Modest Share Price Uptick

Simply Wall St.
·
Nov 03, 2025

A Closer Look at BioCryst Pharmaceuticals (BCRX) Valuation After Recent Share Price Movement

Simply Wall St.
·
Oct 25, 2025

BioCryst to Present New Pediatric Hae Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting

THOMSON REUTERS
·
Oct 23, 2025

BioCryst Unveils Positive Pediatric HAE Data for Oral Berotralstat at ACAAI 2025

Reuters
·
Oct 23, 2025

Bicara sinks after J&J reports head and neck cancer data

TIPRANKS
·
Oct 21, 2025

BioCryst price target raised to $26 from $24 at Cantor Fitzgerald

TIPRANKS
·
Oct 15, 2025

RBC Raises Price Target on BioCryst Pharmaceuticals to $15 From $14, Keeps Outperform Rating

MT Newswires Live
·
Oct 15, 2025